New hope for kids with hard-to-treat genetic seizures

NCT ID NCT05818553

Ongoing Disease control Sponsor: Praxis Precision Medicines Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine called PRAX-562 in 77 children with rare genetic epilepsies (SCN2A or SCN8A). The goal is to see if it safely reduces motor seizures. The trial has two parts: a double-blind phase where some children get the drug and some get a placebo, followed by an open-label phase where all children can receive the drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCN2A ENCEPHALOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

developmental and epileptic encephalopathy, 11 developmental and epileptic encephalopathy, 13

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCN2A ENCEPHALOPATHY SCN8A ENCEPHALOPATHY

Contacts and locations

Show contact details

Locations

Praxis Research Site

Atlanta, Georgia, 30329, United States
Praxis Research Site

Chicago, Illinois, 60611, United States
Praxis Research Site

Minneapolis, Minnesota, 55113, United States
Praxis Research Site

Hackensack, New Jersey, 07601, United States
Praxis Research Site

Tel Litwinsky, 52621, Israel
Praxis Research Site

Madrid, 28034, Spain
Praxis Research Site

Glasgow, G51 4TF, United Kingdom
Praxis Research Site

London, WC1N 3BH, United Kingdom